2023-11-01 16:13:37 ET
More on Sarepta Therapeutics
- Sarepta Stock Tanks As DMD Gene Therapy Fails Confirmatory Study, Risks Market Withdrawal
- Sarepta's Elevidys: Secondary Outcomes Hold Regulatory Promise
- Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy
- Sarepta Therapeutics Q3 2023 Earnings Preview
- Biggest stock movers today: Caterpillar, Arista Networks, BP, Pinterest and more
For further details see:
Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M